01 6Eligard
02 2Leuplin/Enantone
03 5Leuprorelin
04 8Lupron
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 752
2019 Revenue in Millions : 887
Growth (%) : -15
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 783
2020 Revenue in Millions : 752
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 829
2016 Revenue in Millions : 821
Growth (%) : 1
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 821
2015 Revenue in Millions : 826
Growth (%) : -1
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 778
2014 Revenue in Millions : 826
Growth (%) : 6%
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 892
2017 Revenue in Millions : 829
Growth (%) : 8%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 887
2018 Revenue in Millions : 892
Growth (%) : -1
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : -0.90%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,005
2018 Revenue in Millions : 1,034
Growth (%) : -3
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 117
2019 Revenue in Millions : 128
Growth (%) : -9
LOOKING FOR A SUPPLIER?